Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10294561" target="_blank" >RIV/00216208:11130/15:10294561 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/15:10294561
Result on the web
<a href="http://dx.doi.org/10.1016/j.clbc.2014.07.007" target="_blank" >http://dx.doi.org/10.1016/j.clbc.2014.07.007</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.clbc.2014.07.007" target="_blank" >10.1016/j.clbc.2014.07.007</a>
Alternative languages
Result language
angličtina
Original language name
Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer
Original language description
Efficacy of ixabepilone (n = 40), or ixabepilone with cetuximab (n = 39), as first-line treatment for advanced/metastatic triple-negative breast cancer (TNBC) was assessed. Objective response rates of 30% and 35.9% were observed in the monotherapy and combination arms, respectively. Median progression-free survival was 4.1 months in both arms. Monotherapy and combination therapy demonstrated similar levels of activity, with predictable safety profiles. Background: Despite high initial sensitivity to chemotherapy, TNBC is associated with a poor prognosis, highlighting the need for novel therapeutic strategies. The aim of this multicenter, randomized, open-label phase II trial was to assess the efficacy of ixabepilone as monotherapy, and the combinationof ixabepilone with cetuximab, as first-line treatment in patients with triple-negative locally advanced nonresectable and/or metastatic breast cancer. Patients and Methods: Women were randomly assigned to receive either ixabepilone (40 m
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Clinical Breast Cancer
ISSN
1526-8209
e-ISSN
—
Volume of the periodical
15
Issue of the periodical within the volume
1
Country of publishing house
US - UNITED STATES
Number of pages
8
Pages from-to
8-15
UT code for WoS article
000348012400002
EID of the result in the Scopus database
2-s2.0-84920503993